Robert A. Stoltz, MD
Specialist
- Medicare participating
At a glance
- Medical school
- New York Medical College (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,011
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: New York Medical College
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
GA license 058018
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northside Hospital Atlanta, GA
Medical groups
- Georgia Retina, PC (24 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,011
- Services billed
- 63,091
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 37,200 | 128 |
| Imaging of retina | 2,225 | 855 |
| Injection, aflibercept, 1 mg | 1,464 | 152 |
| Injection of drug into eye | 1,463 | 341 |
| Injection, ranibizumab, 0.1 mg | 930 | 48 |
| Established patient complete exam of visual system | 867 | 661 |
| Established patient problem focused exam of visual system | 227 | 173 |
| Photography of the retina | 224 | 178 |
| New patient office or other outpatient visit, 45-59 minutes | 171 | 171 |
| Established patient office or other outpatient visit, 20-29 minutes | 162 | 128 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Marietta, GA | 101 |
| Latanoprost Other prescribers in Marietta, GA | 53 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Marietta, GA | 50 |
| Atropine Sulfate | 46 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 46 |
| Timolol Maleate Other prescribers in Marietta, GA | 29 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Marietta, GA | 24 |
| Ciprofloxacin Hcl Other prescribers in Marietta, GA | 24 |
| Brimonidine Tartrate Other prescribers in Marietta, GA | 17 |
| Ketorolac Tromethamine Other prescribers in Marietta, GA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 15 payments worth $642 in total to this clinician.
| Ani Pharmaceuticals, Inc. | $310 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $111 |
| Astellas Pharma US Inc | $80.11 |
| Apellis Pharmaceuticals, Inc. | $45.32 |
| Genentech USA, Inc. | $34.41 |
| Alcon Vision LLC | $24.38 |
| Bausch & Lomb Americas Inc. | $22.93 |
| AbbVie Inc. | $13.92 |
| Food and Beverage | $642 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $85,739 in research payments for these studies, mostly to the institutions running them.
- Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
Janssen Research & Development, LLC - New Day Study
Ani Pharmaceuticals, Inc. - Port Delivery System of Ranibizumab Extension Study
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Apellis Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.